Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 27 (Cancelled).

28 (Withdrawn). A cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)



wherein R^5 represents R^{51}, R^{52}, R^{53}, R^{54}, R^{55}, R^{56}, R^{57}, R^{58}, R^{59}, R^{70}, R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, R^{76}, R^{77}, or R^{78}; and R^6 represents hydrogen, R^{62}, R^{63}, R^{64}, or R^{65}:

R^{51} :



R^{52} :



R^{53} :



R^{54} :



R^{55} :



R^{56} :



R^{57} :



R^{58} :



R^{59} :



R^{70} :



R^{71} :



R^{72} :



R^{73} :



R^{74} :



R^{75} :



R^{76} :



R^{77} :



R^{78} :



R^{62} :



R^{64} :



R^{63} :



R^{65} :



29 (Cancelled).

30 (Currently Amended). A method of activating NKT ~~cell~~ cells which comprises administering ~~the cell activator according to claim 28~~ to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)



wherein R^5 represents R^{51}, R^{52} or R^{53}; and R^6 represents hydrogen, R^{62}, R^{63}, R^{64}, or R^{65}:

R^{51} : R^{52} : R^{53} :





31 (Cancelled).

32 (Currently Amended). A method of accelerating IL-4 production which comprises administering ~~the cell activator according to claim 28~~ to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)



wherein R^5 represents R^{51}, R^{52} or R^{53}; and R^6 represents hydrogen, R^{62}, R^{63}, R^{64}, or R^{65}:

R^{51} : R^{52} : R^{53} :





33 (Cancelled).

34 (Currently Amended). A method of accelerating IFN-γ production which comprises administering ~~the cell activator according to claim 28~~ to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)



wherein R^5 represents R^{51}, R^{52} or R^{53}; and R^6 represents hydrogen, R^{62}, R^{63}, R^{64}, or R^{65}:

R^{51} : R^{52} : R^{53} :





35 (Cancelled).

36 (Currently Amended). A method of activating dendritic ~~cell~~ cells which comprises administering the cell activator to claim 28 to a mammal.

37 (Cancelled).

38 (Previously Presented). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 28 to a mammal.

39 (Cancelled).

40 (Previously Presented). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 28 to a mammal.

41 (Cancelled).

42 (Currently Amended). A method of activating NK ~~cell~~ cells which comprises administering the cell activator according to claim 28 to a mammal.

43 (Cancelled).

44 (Withdrawn). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 28 to a mammal.

45 (Cancelled).

46 (Withdrawn). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 28 to a mammal.

47 (Cancelled).

48 (Withdrawn). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 28 to a mammal.

49 (Cancelled).

50 (Current Amended). A method of inhibiting ~~viral~~ herpesvirus activity which comprises administering the cell activator according to claim 28 to a mammal.

51 (Cancelled).

52 (Previously Presented). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 28 to a mammal.

53 (Cancelled).

54 (Current Amended). A method of accelerating ~~NO~~ nitrogen monoxide production which comprises administering the cell activator according to claim 28 to a mammal.

55 (Current Amended). A method of inhibiting ~~viral~~ herpesvirus activity of which comprises administering the cell activator according to claim 28 to a mammal, wherein R^6 represents hydrogen.

56 (Current Amended). A method of inhibiting ~~viral~~ herpesvirus activity which comprises administering the cell activator according to claim 28 to a mammal, wherein R^5 represents R^{51}, R^{52}, R^{53}, R^{54}, R^{55}, and R^{56}.

57 (New). A method in accordance with claim 50 wherein said herpesvirus is cytomegalovirus.

58 (New). A method in accordance with claim 55 wherein said herpesvirus is cytomegalovirus.

59 (New). A method in accordance with claim 56 wherein said herpesvirus is cytomegalovirus.